Abstract 1575P
Background
Exposure to secondhand smoke (SHS) can elevate the overall cancer risk for individuals who have never smoked. Smoke-free policies aim to protect non-smokers from the harmful effects of SHS and align with the guidelines set forth by the World Health Organization (WHO) Framework Convention on Tobacco Control. However, restrictions on smoking in outdoor public places are limited.
Methods
Between 2021 and 2024, the Spanish Association Against Cancer (SAAC) launched a program to enhance smoking prohibitions in outdoor areas. To do so, we first identified public places highly visited by smokers and vulnerable populations. Collaboration agreements were established with city halls, public organizations, and institutions interested in the project. These agreements involved advertising prohibiting smoking and vaping, smoke-free events, and training programs for the personnel responsible for enforcing these recommendations.
Results
Since the program's implementation, 358 collaboration agreements have been signed with 235 city halls through the 52 provinces of Spain. Most agreements (n=129, 36%) were launched to free urban and rural parks and green places from SHS. Other included outdoor sports centers and sports grounds (n=78,22%), universities (n=40,11%), and beaches (n=10, 3%). As a result of the good population and city halls' response to the initiative, the SAAC enforced the inclusion and regulation of outdoor smoke-free places in the new national comprehensive plan for the prevention of smoking.
Conclusions
Population-level initiatives to enforce smoke-free policies in outdoor places can result in new national legislation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Spanish Association Against Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1584P - Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS)
Presenter: Saquib Banday
Session: Poster session 10
1585P - Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Presenter: Giovanni Maria Iannantuono
Session: Poster session 10
1586P - Current status of breast cancer: A comparative analysis between developed and developing countries
Presenter: Ana Isabel Martin Quesada
Session: Poster session 10
1587P - As seen through Hollywood’s lens: Cancer in movies, 2010-2020
Presenter: David Benjamin
Session: Poster session 10
1588P - Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience
Presenter: Sara Di Bella
Session: Poster session 10
1589P - Ramping up phase I trial recruitment: Defining potential barriers and disparities
Presenter: Burak Aktas
Session: Poster session 10
1590P - Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Presenter: Sonia Priou
Session: Poster session 10
1591P - Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024
Presenter: Geetin Majhail
Session: Poster session 10
1592P - Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Presenter: Berna C. Özdemir
Session: Poster session 10
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10